4.3 Review

Antibodies and protein misfolding: From structural research tools to therapeutic strategies

Journal

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Volume 1844, Issue 11, Pages 1907-1919

Publisher

ELSEVIER
DOI: 10.1016/j.bbapap.2014.08.016

Keywords

Amyloid; Neurodegenerative disease; Protein-misfolding; Antibody; Immunotherapy

Funding

  1. Medical Research Council (MRC) [G1002272]
  2. Wellcome Trust
  3. Leverhulme Trust
  4. Elan Pharmaceuticals
  5. National Institutes of Health [NS073415, NS053912]
  6. Hereditary Disease Foundation
  7. Michael J Fox Foundation
  8. High Q Foundation/Cure Huntington's Disease Initiative/CHDI
  9. Biotechnology and Biological Sciences Research Council [BB/H003843/1] Funding Source: researchfish
  10. Medical Research Council [G1002272] Funding Source: researchfish
  11. BBSRC [BB/H003843/1] Funding Source: UKRI
  12. MRC [G1002272] Funding Source: UKRI

Ask authors/readers for more resources

Protein misfolding disorders, including the neurodegenerative conditions Alzheimer's disease (AD) and Parkinson's disease (PD) represent one of the major medical challenges or our time. The underlying molecular mechanisms that govern protein misfolding and its links with disease are very complex processes, involving the formation of transiently populated but highly toxic molecular species within the crowded environment of the cell and tissue. Nevertheless, much progress has been made in understanding these events in recent years through innovative experiments and therapeutic strategies, and in this review we present an overview of the key roles of antibodies and antibody fragments in these endeavors. We discuss in particular how these species are being used in combination with a variety of powerful biochemical and biophysical methodologies, including a range of spectroscopic and microscopic techniques applied not just in vitro but also in situ and in vivo, both to gain a better understanding of the mechanistic nature of protein misfolding and aggregation and also to design novel therapeutic strategies to combat the family of diseases with which they are associated. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody. (C) 2014 The Authors. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available